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ABSTRACT 
The objective of the present study was to fabricate and optimize mucoadhesive buccal film encloses rizatriptan benzoate (RBZ) loaded solid 
lipid nanoparticles (SLNs) for improved ex-vivo permeation. RBZ loaded SLNs were formulated by hot high pressure homogenization method. 
SLNs were characterized for size, zeta potential and scanning electron microscopy (SEM). The RBZ SLNs comprising mucoadhesive buccal film 
were fabricated using dependent variables in different concentration of Eudragit RS100 and HPMC K4M by using solvent evaporation method. 
The formulations were experimentally optimized using two factors, three level statistical design approach. The formulated buccal film 
comprising RBZ SLNs evaluated for mucoadhesive strength, swelling index, drug release and ex vivo permeation. The optimized formulation of 
RBZ SLNs showed particle size, polydispersity index, zeta potential and entrapment efficiency i.e. 228 nm, 0.22±0.02, -14mV, 81.78% 
respectively. Optimized mucoadhesive buccal film formulation followed Korsmeyer-Peppas drug release kinetic model with non-Fickian 
diffusion mechanism. Flux, lag time, permeability values in ex vivo permeation of RBZ from SLNs loaded film were found to be 0.071µg/cm2.h, 
60 min., 0.014 respectively. The flux and permeability values were increased and lag time for permeation was decreased in ex vivo permeation 
studies of RBZ SLNs buccal film as compared to RBZ film. The results of the in vitro and ex vivo permeation study advocate the mucoadhesive 
film comprising RBZ SLNs is encouraging approach for drug delivery to brain targeting diseases.  
Keywords: Solid Lipid nanoparticles; Rizatriptan benzoate; Buccal film; Bioavailability.  
 
Article Info: Received 04 May 2019;    Review Completed 06 June 2019;    Accepted 10 June 2019;    Available online 15 June 2019 
Cite this article as:  
Salve P, Bali N, Fabrication and optimization of buccal film comprising rizatriptan benzoate loaded solid lipid 
nanoparticles for improved ex vivo permeation, Journal of Drug Delivery and Therapeutics. 2019; 9(3-s):636-648     
http://dx.doi.org/10.22270/jddt.v9i3-s.3112                             
*Address for Correspondence:  




Nanoparticles (NPs) are objects in the size range 1-1000 nm 
[1]. NPs favours for transport across biomembranes due to 
their physical properties. The favourable property linked to 
NPs includes multifunctionalization and higher payloads. The 
rationale for development of NPs for brain disorders 
includes their ability to cross blood-brain barrier (BBB). The 
phenomenon depends on physicochemical properties of NPs 
rather than chemical structure of the embedded drug. The 
more acceptability of NPs is due to their chemical and 
biological stability. The higher loading of both hydrophilic 
and lipophilic drugs makes them more feasible for 
development of oral, inhalational, and parenteral dosage 
forms [2]. 
The stable lipid-based nanocarriers provide a hydrophobic 
core for the drug to be dissolved or dispersed in it [3]. The 
solid lipid nanoparticles (SLNs) are comprised of 
triglycerides, fatty acids, and waxes. The size range varies 
between 40-200 nm which favours to cross the tight 
endothelial cells of BBB and avoid the reticuloendothelial 
system (RES) [4]. The molten lipid-containing drug is 
dispersed in an aqueous solution by high-pressure 
homogenization (HPH) leading to generation of 
microemulsion. The advantages of SLNs are their 
biocompatibility, higher drug entrapment efficiency and 
provide continuous drug release for weeks [5]. 
Migraine is an episodic syndrome results from 
dysfunctioning of sympathetic nervous system [6]. The 
etiology of migraine is not well understood. The suggested 
mechanisms of migraine are neurovascular theory and 
cortical spreading depolarization theory [7]. The symptoms 
of migraine are one sided primary headache, vomiting, 
nausea and environmental reactivity [8].      
Oral drug delivery being highly patient compliant also suffers 
from the hepatic first pass metabolism [9,10]. The oral route 
has some disadvantage for certain drugs due to extensive 
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pre-systemic metabolism in liver, which often leads to lack of 
significant correlation between membrane permeability, 
absorption and bioavailability [11]. 
Buccal route provides the direct access to systemic 
circulation through the jugular vein bypassing the hepatic 
first-pass metabolism leading to enhanced bioavailability of 
drug. Other advantages of buccal route includes excellent 
accessibility, low enzymatic activity, painless administration, 
easy withdrawal, addition of permeation enhancer/enzyme 
inhibitor or pH modifier in buccal formulations, versatility in 
designing as multidirectional or unidirectional release 
systems for local or systemic action [12]. Recently, the 
nanoparticles based buccal drug delivery system has 
generated increased interest. The advantages of solid lipid 
nanoparticles in combination with advantage of buccal route 
of drug administration can result in enhanced permeation 
across buccal mucosa [13]. 
The buccal films provide the advantage of small size 
thinness, flexibility resulting in patient compliance as 
compared to tablets. The buccal films can maintain extensive 
contact with buccal mucosa to enhance the bioavailability of 
drug [14].      
RBZ is an anti-migraine and anti-inflammatory agent used in 
the treatment of acute migraine attacks. It stimulates 
presynaptic 5-HT1D receptors, which serves to inhibit both 
vasodilatation and inflammation. After oral administration, it 
undergoes extensive hepatic first-pass metabolism to 
inactive indole acetic acid derivative resulting into decreased bioavailability ȋ≈ Ͷͷ%Ȍ [15].  
The available researches on solid lipid nanoparticles 
containing RBZ have been reported by [16]. The mucosal 
drug delivery of RBZ has been reported by [17]. The buccal 
drug deliveries of RBZ using solid lipid nanoparticles have 
not been investigated or characterized and clear need exists 
for development of RBZ embedded SLNs. In order to enhance 
the buccal permeation of RBZ, we envisaged to develop and 
characterize the buccal film containing RBZ embedded SLNs.  
MATERIALS AND METHOD 
Materials 
RBZ was obtained as a gratis sample from Mylan 
Laboratories, Hyderabad, India. Stearic acid and tween 80 
were obtained from Merck India Ltd, India. Eudragit RS100 
was obtained as gift sample from Evonik Industries, India. 
HPMC K4M was kindly received from Colorcon, India. All 
other chemicals and solvents were of analytical grade and 
were procured from Merck India Ltd. All the materials were 
used as received. Purified water was obtained using Milli-Q 
water purification system. 
Methods 
Differential scanning calorimetry (DSC) studies 
DSC thermogram of RBZ, stearic acid and their physical 
mixture were recorded using Mettler-Toledo DSC apparatus, 
Zurich, Switzerland. A sample (5 mg) was weighed into aluminium pans and subjected to heating at a rate of ͳͲ ℃/ min from ͵Ͳ ℃ to ͶͲͲ ℃. Nitrogen gas at a flow rate of ͶͲ 
ml/min was used as a purge gas in DSC analysis [18]. 
FT-IR spectrometry studies 
In FT-IR studies, RBZ and stearic acid were individually 
triturated and mixed well with potassium bromide in 1:1 
ratio. The samples were compressed under 
10 t/nm2 pressure and scanned in 400 to 4000 cm−1 
stretching frequency range. The FT-IR spectrum of physical 
mixture was compared with spectrum of RBZ and stearic 
acid. The shift in the stretching frequency of RBZ in presence 
of stearic acid was investigated to determine physical 
interactions between RBZ and stearic acid [19]. 
Solubility studies of drug in lipids 
Stearic acid, 1g was added to test tube and heated in a controlled temperature water bath at ͺͲ ͼC. RBZ was added 
in to molten stearic acid with gentle shaking till molten 
phase was saturated with it. Solubility of drug was 
determined in mg/g of lipid. Same procedure was followed 
for glyceryl monostearate, compritol 888 ATO. The lipid 
which showed maximum solubility of RBZ was selected for 
preparation of SLNs [20]. 
Preparation of drug loaded SLNs  
SLNs were prepared by high pressure homogenization 
method with some modifications [21,22]. Stearic acid was 
melted and kept in water bath at 80 ℃. )n the molten lipid 
phase, weighed amount of RBZ was added. The aqueous 
phase was comprised of tween 80 dissolved in purified water, previously heated at ͺͲ ℃. The molten hot lipid phase 
was dispersed in hot surfactant phase and obtained the pre-
emulsion under high speed homogenizer (Ultra turrax T18, )KA, GermanyȌ at ͳͶͲͲͲ rpm at ͺͲ ℃ for Ͷ min. The warm 
pre-emulsion was introduced in high pressure homogenizer 
at 500 bar pressure for 6 cycles to form the SLNs dispersion. 
The SLNs dispersion formed was allowed to cool at room 
temperature (Table 1). 
 
Table 1 Formulation Composition 
Sr. No Ingredients AR1 AR2 AR3 
1 Rizatriptan benzoate (mg) 80 80 80 
2 Stearic acid (%w/w) 3 3 3 
3 Tween 80 (%v/v) 1 2 3 
4 Distilled water q.s q.s q.s 
 
Freeze-drying of SLNs       
The SLNs dispersion was mixed with 3 %w/v mannitol as 
cryoprotectant and subjected to deep freezing at (–Ȍ ͸Ͳ ℃. 
The frozen sample was moved for drying process in freeze-
dryer. The drying period was conducted for 72 h by applying 
100 mTorr vacuum. The freeze dried SLNs were used for 
analysis and incorporation in buccal films. 
 
Characterization of lyophilized SLNs 
Particle size and zeta potential  
For measurement of particle size of SLNs, a 5 mg sample of 
lyophilized SLNs was dispersed in 10 ml deionized water. 
The mean diameter, polydispersity index and zeta potential 
values were determined using Malvern Zetasizer Nano ZS, 
Malvern Instrument (Malvern, UK) [23,24]. 
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Entrapment efficiency and loading capacity  
A back calculation method was used for measurement of 
entrapment efficiency. In an allomer tube, 2 ml dispersion was placed and centrifuged at ͺͲ,ͲͲͲ rpm for Ͷͷ min. at Ͷ ℃. 
The amount of RBZ in aqueous medium was estimated 
spectrophotometrically at 232 nm. The percent entrapment 
efficiency (%EE) and percent drug loading (%DL) of RBZ 
were calculated as per equation (2) and (3) respectively [25]. 
% EE =
                   –                                                    
Equation (2)  
% DL 
=
                   –                                                                                                       
Equation (3) 
DSC studies  
DSC thermogram of RBZ, stearic acid, RBZ–stearic acid 
physical mixture and RBZ embedded SLNs were recorded 
using a differential scanning calorimeter DSC 823 Mettler 
Toledo, Mettler Ltd. The thermal behaviour was studied by 
heating 2.0 ± 0.2 mg of individual sample in a covered 
sample pan under nitrogen gas flow. The thermograms were recorded over the temperature range ͵Ͳ ℃ - ͵ͲͲ ℃ at a 
heating rate of ͳͲ ℃/min. The thermogram of RBZ was 
compared with thermograms of physical mixture and SLNs 
[26]. 
FT-IR spectrometry  
The FT-IR spectra of RBZ, stearic acid and RBZ embedded 
SLNs were recorded using Shimadzu-IR AFFINITY FT-IR 
spectrophotometer. The samples were triturated and mixed 
well with potassium bromide in 1:1 ratio. The triturated 
sample was introduced in sample holder and scanned in the 
range 4500-500 cm-1. The spectrum of SLNs was compared 
to the spectra of RBZ, lipid and their physical mixtures [25]. 
Scanning electron microscopy (SEM) 
The surface morphology and structure were visualized by 
scanning electron microscopy (SEM) (EVO 18, Carl Zeiss, 
Germany). SEM images of RBZ and SLNs were recorded after 
coating with gold/palladium in vacuum beforehand at 2 and 
20 KeV accelerating voltage [27]. 
Preparation of SLNs loaded buccal film  
Buccal films containing RBZ SLNs were prepared by solvent 
casting technique [28]. The calculated amount of HPMC K4M 
was dispersed 10 ml 95 %v/v ethanol with continuous 
stirring using magnetic stirrer in a separate beaker. To it, 
polyethylene glycol 400 was added as a plasticizer in 
proportion to 30 %w/w of polymer weight. The weighed 
amount of Eudragit RS100 was dissolved in 10 ml 95 %v/v 
ethanol and to it triethyl citrate was added as a plasticizer in 
proportion to 20 % w/w of polymer weight. The above two 
solutions were mixed. The calculated amount of RBZ SLNs 
was incorporated in the mixed polymeric solution after 
levitation. The bubbles were removed with aid of sonicator. 
The solution was casted onto petri dish and dried at 25 ℃ for 
24 h. The glass transition temperature of Eudragit RS100 is 
in the range 28-͵ʹ ℃, hence the film was dried well below its 
glass transition temperature. The films were cut into size of 
diameter 1.5 cm containing SLNs equivalent to 5 mg RBZ. 
The prepared films were packed in aluminium foil and stored 
in an airtight glass container to maintain the integrity and 
elasticity of films. 
 
Experimental design 
A full factorial design for two factors at three levels each was 
selected to optimize response of variables. The two factors, 
the mucoadhesive polymer (g) and sustained release 
polymer (g) used were varied and the factor levels were 
suitably coded. The % cumulative release, mucoadhesive 
strength and swelling index were taken as the response 
variables. In the design, the two factors were evaluated each 
at three levels and experimental trials were performed for 
possible combinations. All other formulation variables and 
processing variables were kept constant throughout the 
studies.                       
The formulae were developed as 9 sets varying the variables 
following 32 full factorial design (3 levels) using Design 
expert. Dependent variables were Y1 = % cumulative release, 
Y2 = mucoadhesive strength and Y3= swelling index. The 
effect of two independent variables HPMC K4M (X1) and 
Eudragit RS100 (X2) on the responses (Y1, Y2, Y3) were 
observed. The levels of all other ingredients in the 
formulation were fixed. 
Evaluation of buccal films 
Film thickness            
The thickness of buccal film was measured at four corners 
and in centre of film (total five locations using dial gauge.) 
Average of five readings was taken as thickness of film [29]. 
Folding endurance  
The folding endurance was measured manually for prepared 
films. Films were repeatedly folded at the same place till it 
breaks. The number of times the film could be folded at the 
same place without breaking was the folding endurance 
value [30]. 
Surface pH study  
           Buccal films were allowed to swell for 2 h in pH 6.8 
phosphate buffer solution. The glass electrode of pH meter 
was placed on the surface of the swollen film. A mean of 
three pH readings was recorded [12]. 
Swelling index  
Buccal film was kept in a petri dish containing 50 ml of pH 
6.8 phosphate buffer solution. The cover slip was removed 
and weighed after each hour till period of 6 h. The difference 
in the weights was recorded as weight gain due to absorption 
of water. The swelling index of film as per equation (4)                          ................(4) 
Where, W2 is the weight or area of the swollen film after time 
t and W1 is the original film weight [31].  
Determination of drug content  
The films were investigated for RBZ content uniformity by 
UV spectrophotometry [31]. Circular pieces of films of 1.5 cm 
diameter were cut from three different places from the 
casted film. Each sample film piece was placed in 100 ml 
volumetric flask and dissolved in pH 6.8 phosphate buffer. 
From it, 0.2 ml was withdrawn and diluted with pH 6.8 
phosphate buffer up to 10 ml. The absorbance of solution 
was measured at 225 nm using uv/visible 
spectrophotometer (Shimadzu UV-1700). The percent RBZ 
content was determined using standard calibration curve 
and procedure was repeated for three films of each 
formulation.  
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Ex Vivo mucoadhesive strength  
A modified balance method was used for determining the ex 
vivo mucoadhesive strength. Fresh goat buccal mucosa was 
obtained from a local slaughterhouse and used within two 
hours of slaughter. The mucosal membrane was separated by 
removing the underlying fat and loose tissues. The 
membrane was washed with distilled water and then with 
pH 6.8 phosphate buffer. A piece of buccal mucosa was 
pasted to the glass beaker using an instant adhesive and held 
on the right side of the balance. The film was stuck to the 
lower side of the glass petri dish with instant adhesive. The 
right hand pan was balanced by adding weights on the left 
hand pan. Weights were slowly added to the left-hand pan 
until the film was detached from the mucosal surface. The 
weight in gram required to detach the film from the mucosal 
surface was recorded as the mucoadhesive strength [32].  
Ex Vivo permeation study  
 The ex vivo buccal permeation studies of RBZ film and RBZ 
embedded SLNs film were performed using a Franz diffusion 
cell at 37±0.5 ℃. A fresh goat buccal mucosa was obtained 
from local slaughter house and used within two hours of 
slaughter. Freshly obtained goat buccal mucosa of 1.77 cm2 
surface area was mounted between the donor and receptor 
compartments. The buccal film containing RBZ and RBZ SLNs 
were individually placed on the mucosal side and the 
compartments were clamped together. The receptor 
compartment (20 ml capacity) was filled with pH 6.8 
phosphate buffer and the hydrodynamics in the 
compartment was maintained by stirring at 50 rpm with a 
magnetic bead. A 3 ml sample was withdrawn at 
predetermined time intervals and analyzed for RBZ content 
by uv/visible spectrophotometer using blank [28]. 
Dissolution study 
The dissolution studies of SLNs embedded buccal films were 
carried using USP Dissolution Test Apparatus Type –II. The 
films were attached mid-way of test apparatus using 
adhesive glue. The dissolution medium used was 500 ml of simulated saliva fluid maintained at ͵͹±Ͳ.ͷ ℃ and stirred at 
50 rpm. The samples were withdrawn after every 30 minutes 
and replaced with an equal volume of fresh dissolution 
media. The withdrawn samples were analyzed 
spectrophotometrically at 225 nm [33]. 
RESULTS AND DISCUSSION 
Differential scanning calorimetry (DSC) 
The DSC thermogram of RBZ shown an endothermic with 
onset at 179.63 ℃ and end set at ͳͺʹ.͹ͻ ℃. The endothermic melting was observed at ͳͺͲ.ͺͶ ℃. The corresponding 
enthalpy value was found to be (-) 122.69 Jg-1 (Fig 1 A). Stearic acid shown melting endotherm at ͷ͹.͹Ͳ ℃ with onset at ͷͷ.͸͵ ℃ and end set at ͸Ͳ.ͺ͵ ℃. The corresponding 
enthalpy for thermal transition was found to be (-) 252.02 Jg-
1 (Fig 1B). The endotherm of physical mixture of RBZ and 
stearic acid in 1:1 ratio shown the melting endotherm at ͷ͹.͹Ͳ ℃ with onset at ͷͷ.͸͵ ℃ and end set at ͸Ͳ.Ͳ͵ ℃. The 
corresponding enthalpy value was found to be (-) 251.02 Jg-1 
(Fig 1C). The lyophilized SLNs containing RBZ shown an endothermic endotherm at ͸ͷ.ͻͶ ℃ with onset at ͻͲ.ͻ͸ ℃ and end set at ͳͳʹ.ͺʹ ℃ with enthalpy value of ȋ-) 255.20 Jg-1 
(Fig 1D).  
The shifting of melting endotherm of RBZ from ͳͺͲ.ͺͶ ℃ to ͷ͹.͹Ͳ ℃ was observed in DSC studies of physical mixture of 
RBZ with stearic acid. It indicated the complete solubilization 
of drug in the stearic acid. Similarly, the enthalpy value of 
RBZ was found to be decreased from (-) 122.6 to (-) 251.02 
Jg-1 which was near to enthalpy of stearic acid i.e. (-) 252.02 
Jg-1. In case of the lyophilized SLNs containing RBZ, the 
melting endotherm was shifted to lower temperature at ͸ͷ.ͻͶ ℃. The enthalpy value in case of lyophilized SLNs 
containing RBZ was found to be near to the enthalpy of 
stearic acid and physical mixture. The above observations 
concluded the complete solubilization of RBZ in stearic acid 
phase has occurred. 
FT-IR studies 
In the FT-IR studies, the characteristic stretching frequencies 
of RBZ  viz. N-H stretching at 2920 cm-1, C=N stretching at 
1640 cm-1 were observed (Fig 2A). The stretching 
frequencies of stearic acid viz. O-H stretching (carboxylic 
acid) at 2848cm-1, O-H stretching (alcohol) at 3600 cm-1  
were observed (Fig 2B). The characteristic stretching 
frequencies of RBZ were found to be disappeared due to 
interaction with stearic acid (Fig 2C). The disappearance of 
stretching frequencies of RBZ indicated its solubilization in 
stearic acid. 
Solubility studies of drug in lipids 
Solubility of drug in lipid determines the degree of drug 
loading in lipid. The lipids were screened for solubility of 
RBZ at 70 ℃. The solubility of drug in glyceryl monostearate, 
stearic acid, compritol 888 ATO was found to be 48.9±0.67, 
92.±0.96, 11.8±0.88 mg/g of solid lipid respectively. As 
solubility of drug was maximum in stearic acid, it was used 
for preparation of SLNs. 
Preparation of SLNs 
This study reports a hot high pressure homogenization 
process for preparation of RBZ SLNs and investigates effect 
of surfactant concentration on drug loading. 
Characterization of SLNs 
SLNs provide prolong stability, drug release control and 
incorporates hydrophilic and lipophilic drugs. The prepared 
SLNs were subjected to particle size and zeta potential 
measurements.  
Particle size 
The formulations AR1, AR2, and AR3 showed the decrease in 
particle size with an increase in surfactant concentration 
[34]. The increasing concentration of surface active agent 
decreases surface tension and provides stability to created 
particles during homogenization process [35]. The 
formulation batches AR1, AR2 and AR3 contained tween 80 in 
1, 2 and 3 %w/v concentration respectively. The particle size 
of formulations AR1, AR2 and AR3 were found to be 509.6 nm, 
253.9 nm, and 228.9 nm respectively. The surfactant tween 
80 in 3 %w/v concentrations showed decreased particle size 
(AR3) as compared to formulations AR1 and AR2 containing 
1 and 2 % w/v tween 80. Similarly, the polydispersity index 
(PDI) of formulations was found to decrease with an increase 
in tween 80 concentrations. The optimized formulation AR3 
shown PDI value 0.493 which was the least value as 
compared to formulations AR1 and AR2. Formulation AR3 
was subjected to lyophilization process. The particle size 
distribution graph of formulation AR3 is shown in figure 3A. 
Zeta potential 
The zeta potential is measure of surface charge present on 
the particles. The zeta potential values of formulations 
studied was found to range from (-) 1.4 to (-) 14 mV 
indicating that the agglomeration of particle was not occur. 
The formulations AR1, AR2 and AR3 showed an increase in 
zeta potential value with an increase in tween 80 
concentrations [36]. Colloidal dispersions with zeta potential 
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values in the range (-) 30 mV to (+) 30 mV are considered to 
be stable (Fig 3B). The formulation AR3 was selected as 
optimized formulation having (-) 14 mV zeta potential value. 
DSC studies of lyophilized SLNs  
In DSC studies, a melting endotherm of RBZ was observed at ͳͺͲ.͵Ͷ ℃. The melting endotherm of stearic acid was observed at ͷ͹.ʹͶ ℃. The comparison of melting endotherm 
clearly concludes the shifting of endotherm to lower 
temperature, ͸ͷ.ͻͶ ℃. )t indicates formation of SLNs. The 
enthalpy value in case of lyophilized SLNs containing RBZ 
was found to be near to the enthalpy of stearic acid and 
physical mixture. The above observations concluded the 
complete solubilization of RBZ in stearic acid phase has 
occurred.  
FT-IR spectrometry studies of lyophilized SLNs 
In the FT-IR spectrum of lyophilized SLNs, an intermolecular 
interaction between SLNs and mannitol was observed as 
indicated by O-H stretching at 2848 cm-1. This stretching 
frequency was observed due to the formation of a hydrogen 
bond between the O-H group of the mannitol with polar head 
group of stearic acid (Fig 2D). 
SEM studies of lyophilized SLNs  
Scanning electron microscopic (SEM) image of RBZ and SLNs 
are shown in figure 4A and 4B respectively. In the SEM image 
of RBZ, irregular shape particles in 20 µm magnification 
were observed.  Whereas, SEM image of lyophilized SLNs 
shown a perfectly spherical solid lipid nanoparticles in 100 
nm magnification. The SLNs were found to be smooth and 
surface integrity was observed. 
Preparation of SLNs loaded buccal film 
Previous reported studies revealed buccal films containing 
RBZ. We developed buccal films containing RBZ embedded 
SLNs using a blend of HPMC K4M and Eudragit RS100 
polymers. The films were found to be smooth, thin, and 
flexible. The surface of the films was found to be fairly 
homogeneous with limited entrapped air bubbles. The films 
containing drug embedded SLNs were found to be slightly 
opaque as compared to films containing SLNs.      
Experimental design 
The formulations were prepared as 9 sets using two 
variables following 32 factorial designs. Buccal films 
containing SLNs were prepared by solvent evaporation 
technique.  
The optimized formulations selected by the design were 
prepared and the parameters were compared to the 
expected values. The results are shown in table 3. For 
systematic investigation of the factors, a full factorial design 
was employed. 
The effect on % cumulative release (Y1) was observed to be 
significant by ANOVA and the polynomial equation was 
found to follow equation 5.  
Y1= 81.14 - 3.53333A - 10.6233B + 1.3325AB   -------(5) 
The terms A and B indicate concentrations of polymers 
HPMC K4M and Eudragit RS100 respectively. As shown in 
equation 5, the negative sign with terms A and B indicated an 
inverse relationship between concentration of polymers and 
% CR. As the concentrations of both polymers were 
increased, the % CR was found to be decreased. For response 
Y1 as shown in table 4, the coefficient of determination value 
(R2) was found to be 0.9068 indicating a good fit agreement 
between concentrations of polymers and % CR. The surface 
response (3D) plot of % CR and its contour plot are shown in 
figure 5A and 5B respectively. 
The effect on mucoadhesive strength (Y2) was observed to 
be significant by ANOVA and the polynomial equation was 
found to follow equation 6. 
Y2= 28.8178 + 6.42 A - 3.57B + 1.54AB     ----------(6) 
The term A indicates concentration of HPMC K4M whereas, 
term B indicates concentration of Eudragit RS100. By 
analyzing the equation, the positive response was observed 
for mucoadhesive strength with HPMC K4M. In case of 
Eudragit RS100, a negative response indicating the 
decreased mucoadhesive strength was observed with an 
increase in Eudragit RS100 concentration. The coefficient of 
determination was found to be value (R2) 0.9924 indicated 
the best fit agreement between effect of polymers on 
mucoadhesive strength. The surface response (3D) plot of 
mucoadhesive strength and its contour plot are shown in 
figures 5C and 5D respectively.      
The effect on swelling index (Y3) was observed to be 
significant by ANOVA and the polynomial equation was 
found to follow equation 7.   
Y3= 77.7511 + 12.9633A - 10.9183B + 4.4325AB --------(7)  
The term A indicates concentration of HPMC K4M whereas 
term B indicates concentration of Eudragit RS100. By 
analyzing the equation, a positive response was observed for 
swelling index with increasing concentration of HPMC K4M. 
In case of Eudragit RS100, a negative response indicating the 
decreased swelling index was observed with an increase in 
Eudragit RS100. The coefficient of determination (R2) was 
found to be 0.9235 indicating the good fit agreement 
between effects of polymers on swelling index. The surface 
response (3D) plot of swelling index and its contour plot are 
shown in figures 5E and 5F respectively. 
The p-values for % cumulative release, mucoadhesive 
strength and swelling index were found to be 0.005, < 0.0001 
and 0.0032 respectively. Thus the P-values were found to be 
significant. The results of statistical analysis are shown in 
table 4. 
Evaluation of buccal film containing RBZ loaded SLNs 
Film thickness and folding endurance  
The thickness of buccal film (PF8) were found to be 0.29 ± 
0.99 mm. Folding endurance was considered adequate to 
reveal good film properties. The films showed folding 
endurance values in the range 199-228 [37]. 
Surface pH and swelling index 
The surface pH of buccal film was found to be 6.7 ± 0.003. 
The importance of swelling property lies in the bioadhesion 
phenomenon. The bioadhesion of film on mucous membrane 
occurs due to swelling, disentanglement and relaxation of 
polymer chains [38,31].The hydration rate and water uptake 
in the formulation F4 was found to be highest. The maximum 
proportion of HPMC K4M and minimum proportion of 
Eudragit RS100 favoured more water penetration resulting 
in enhanced swelling. The swelling index of formulations F4 
was found to be 95.77 ± 2.89% (Fig. 8) 
Mucoadhesive strength  
Adhesive force determines mucoadhesive property. The 
mucoadhesion theory involves diffusion and water 
penetration in polymeric film. The faster rates of hydration 
and swelling equilibrium of films are important factors for 
mucoadhesive property [39,40]. The increased swelling 
index of film was found to contribute to enhanced 
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mucoadhesion. The nanoparticle size in SLNs contributed for 
faster water penetration and resulted in mucoadhesive force. 
The water solubility of RBZ played significant role by 
permitting more water influx in films. As the amount of 
HPMC K4M was increased, the mucoadhesion was found to 
be increased. The increasing amount of Eudragit RS100 has 
shown decreasing mucoadhesive strength due to its 
hydrophobic character. Peak detachment force is the 
maximum applied force at which the film detaches from 
membrane. The mucoadhesive strength for formulation F4 
was found to be 37.63 ± 1.99 g. In this formulation the HPMC 
K4M in its highest proportion contributed to the swelling 
and penetration of the film in the mucous membrane 
resulting in enhanced mucoadhesion (Fig 9). 
Ex vivo diffusion study  
 In the ex vivo diffusion studies of film containing RBZ and 
RBZ loaded SLNs, the flux, lag time and permeability values 
were determined. The lag time for permeation of RBZ film 
was found to be 90 min. The RBZ embedded SLNs film has 
shown lag time of 60 minutes. The drug diffusion was found 
to increase from film formulations containing RBZ embedded 
SLNs.  The film containing SLNs shown enhanced drug 
diffusion across skin as compared to be film containing RBZ.  
The inclusion of RBZ embedded SLNs was found to enhance 
diffusion across skin as compared to the diffusion of RBZ. 
The drug diffusion was found to vary from 44 to 97 % in 300 
min diffusion studies (table 5). The flux value for film 
containing RBZ was found to be 0.045 mg/cm2.h. The SLNs 
embedded RBZ film formulation shown the flux value 0.071 
mg/cm2h. The permeability values where obtained by 
dividing the flux values of RBZ films and SLNs embedded 
RBZ films by the donor phase concentration of the drug 
present in film i.e. 5 mg RBZ. The permeability values found 
to be 0.009 and 0.0142 for RBZ film and SLNs embedded RBZ 
films respectively. The difference factor in the permeability 
was found to be 0.0052. An enhancement by 57.8 % in the 
permeability value was observed in SLNs embedded 
formulation as compared to RBZ formulation (Fig 7).  
In vitro drug release studies 
The in vitro release studies were carried up to 300 min. The 
amount of drug release was found to vary from 65.63 to 
95.14 % (table 3). In the first hour of release studies, less 
than 20 % drug release was observed in formulations 
containing 150 mg Eudragit RS100 (formulations F5, F6, and 
F8). The formulations containing 50 mg Eudragit RS100 has 
shown faster dissolution profile as evidenced in formulations 
F3, F4, F9. An increasing proportion of Eudragit RS 100 was 
found to retard the drug release. The formulation F8 shown a 
better control on drug release from film formulation and 
hence considered as optimized formulation (Fig 6). 
Formulation F8 contained HPMC K4M as a hydrophilic 
sustained release polymer and Eudragit RS100 as 
hydrophobic release retarding agent. The effect of the 
hydrophobic and hydrophilic characteristic of polymers used 
in film contributed for the drug release control. The 
optimized formulation F8 showed Korsmeyer-Peppas drug 
release kinetic model with non-Fickian diffusion mechanism 
as a best fit model. The R2 value was found to be 0.9910. 
 
Table 2 Percent Encapsulation Efficiency and loading Capacity of Formulations (AR1 - AR3) 
Formulation code % RBZ loading % Encapsulation efficiency 
AR1 4.99 ± 0.45 70.10 ± 0.56 
AR2 5.85 ± 0.42 76.11 ± 0.33 
AR3 6.55 ± 0.32 81.78 ± 0.32 
 
Table 3 Experimental Design and Parameters for 32 Factorial Design 
Formulation 
Batches 










F1 300 100 86.46 ± 1.77 67.81 ± 3.09 23.39 ± 2.17 
F2 500 100 81.27 ± 2.39 92.38 ± 2.64 34.73 ± 3.06 
F3 400 50 90.36 ± 1.73 92.11 ± 1.37 32.56 ± 2.91 
F4 500 50 84.47 ± 2.93 95.77 ± 2.89 37.63 ± 1.99 
F5 300 150 72.97 ± 3.53 53.12 ± 2.24 16.82 ± 2.67 
F6 400 150 65.63 ± 2.85 58.69 ± 1.64 25.58 ± 2.86 
F7 400 100 86.33 ± 3.11 73.26 ± 2.60 28.04 ± 2.42 
F8 500 150 67.63 ± 2.98 88.59 ± 3.19 33.49 ± 1.88 
F9 300 50 95.14 ± 3.77 78.03 ± 2.30 27.12 ± 3.13 
Values expressed as mean ± S.D., n = 3. 
 
Table 4 ANNOVA for response surface quadratic model for optimization of mucoadhesive buccal film 
Response Model DF CI SE P-Value SD R2 Value 
Y1 2FI 1 87.61 1.87 0.005 3.95 0.9068 
Y2 2FI 1 32.92 0.34 <0.0001 0.72 0.9924 
Y3 2Fi 1 88.47 2.58 0.0032 5.46 0.9235 
Y1= Cumulative Release, Y2= Mucoadhesive Strength, Y3= Swelling Index, CI= Class Interval, SE= Standard Error, P= Calculated 
Probability, SD= Standard Deviation, R2= Coefficient of Determination 
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Table 5 Percent Diffused of RBZ and RBZ SLNs from Film 
Time (min) % Cumulative RBZ diffused from film % Cumulative RBZ diffused from film containing 
SLNs 
0 0.0000 0.000 
30 1.4850 ±3.57 1.900 ±2.98 
60 1.8700 ± 4.11 2.530±3.86 
90 2.3000 ± 3.58 13.693±2.74 
120 5.6900 ± 2.38 21.663 ±2.64 
150 11.5700 ± 3.06 30.561 ±2.37 
180 17.0530 ±3.55 37.512 ±3.92 
210 24.2300 ± 4.39 46.592 ±3.22 
240 32.3000 ± 3.44 51.450 ±2.97 
270 37.1490 ± 3.95 59.506 ±4.27 
300 42.0100 ± 2.70 66.015 ±3.51 
Values expressed as mean ± S.D., n = 3. 
 
Fig. 1   Represents DSC thermogram of RBZ (A), stearic acid (B), physical mixture of RBZ and stearic acid (C) and lyophilized 
SLNs comprising RBZ (D). Thermal behavior of lyophilized SLNs showed that complete solubilization of RBZ in stearic acid 
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Fig. 2   FTIR spectra for RBZ (A), stearic acid (B), physical mixture of RBZ and stearic acid (C) and lyophilized SLNs comprising 
RBZ (D) showing characteristic peaks at various numbers 
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Fig. 3   Intensity-based particle size distribution for RBZ comprising SLNs (A) with dynamic light  scattering on zetasizer® and 
zeta potential distribution for RBZ comprising SLNs (B) with respect to total counts measured using zetasizer® software 
 
 
Fig. 4   Scanning electron microscopic images of RBZ showing bulk irregular shape phases (A), and  lyophilized RBZ SLNs (B) 
showed spherical shape particles. Scale bar: A-20 µm, B-100 nm 
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Fig. 5   The response surface plot (A,C,E) and contour plot (B,D,F) showing relationship between  concentration of HPMC K4M (X1) and 
Eudragit RS100 (X2) on cumulative release (Y1), mucoadhesive strength (Y2) and swelling index (Y3). (A,B): effect of (X1) and 
(X2) on (Y1); (C,D): effect of (X1) and (X2) on (Y2); (E,F): effect of (X1) and (X2) on (Y3). 
 
Fig. 6   Represents the cumulative drug dissolution. Effect of different concentration of Eudragit RS100 i.e. 50 mg, 100 mg, 150 
mg on formulation batches F1 to F9. In vitro drug dissolution pattern was studied by USP dissolution test apparatus 
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Fig. 7   Represents the cumulative drug diffusion. Effect of RBZ film and RBZ SLNs comprising film showed the lag time and 
significance difference on permeability. Drug diffusion pattern was studied by Franz diffusion cell at 37±0.5 ℃ 
 
Fig. 8   Represents the swelling index. Effect of different concentrations of HPMC K4M i.e. 300 mg, 400 mg, 500 mg on 
formulation batches F1 to F9. Swelling index pattern was studied at different time interval 
 
Fig. 9   Represents the mucoadhesive strength. Effect of different concentration of HPMC K4M i.e. 300 mg, 400 mg, 500 mg on 
formulation batches F1 to F9. Mucoadhesive strength pattern was studied by modified balance method 
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CONCLUSION 
The aim of this study was to develop buccal film 
formulations containing RBZ embedded SLNs. The objectives 
were to identify the optimal parameters like lipid solubility, 
surfactant concentration, particle size, zeta potential, 
mucoadhesive strength, and ex vivo diffusion. Also the 
objective was to compare the ex vivo diffusion of RBZ 
embedded SLNs with the buccal film containing RBZ. In this 
study, the ex vivo permeation of RBZ embedded SLNs were 
conducted. The highest solubility of RBZ was found in stearic 
acid. In preformulation work, the DSC and FT-IR studies 
revealed complete solubilization of RBZ in stearic acid. SLNs 
were prepared using tween 80 as a surfactant in varying 
concentration. A reduction in particle size was observed 
with tween 80. A least particle size distribution averaging to 
228.9 nm was observed with 3 %w/v tween 80.  The zeta 
potential value of (-) 14 mV was observed with 3 % tween 
80 providing stability to the SLNs. The zeta potential value of 
developed SLNs was found to increase with an increase in 
tween 80 concentration. The SEM image of lyophilized SLNs 
shown regular spherical size solid lipid nanoparticles with 
smooth surface. The optimized batch of SLNs was used for 
optimization of formulation of buccal patch using 32 full 
factorial designs. Mucoadhesive strength was found to be 
increased with increased HPMC K4M concentration. The 
maximum mucoadhesion was observed with minimum 
concentration of Eudragit RS100 used in preparation of 
buccal films. Similarly the swelling index was found to 
increase with an increase in HPMC K4M.  Mucoadhesion and 
swelling index studies were found to increase the 
permeation of RBZ across buccal mucosa. The response plots 
for percent cumulative release, mucoadhesive strength and 
swelling index were found to follow 2FI of statistical analysis 
model. The ex vivo permeation of RBZ embedded SLNs 
buccal film was found to be enhanced as compared to RBZ 
buccal film. The release kinetic study revealed that 
optimized formulation followed Korsmeyer-Peppas drug 
release kinetic model with non-Fickian mechanism. The 
developed RBZ loaded SLNs formulation makes it more 
convenient to cross the blood brain barrier. Hence provides 
the promising approach for the delivery of RBZ in the brain. 
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